moxifloxacin has been researched along with cyclosporine in 12 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 377 | 2 | 170 |
| 3,157 | 552 | 1,690 | 30,547 | 3,802 | 6,558 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Neiberg, MN; Sowka, J | 1 |
| Basile, V; Capone, D; Carrano, R; Federico, S; Kadilli, I; Nappi, R; Polichetti, G; Sabbatini, M; Tarantino, G | 1 |
| Bauer, S; Delesen, H; Kubitza, D; Mai, I; Roots, I; Stass, H | 1 |
| Bielory, L; Kumar, S; Syed, BA | 1 |
| Gregory, DG | 1 |
2 review(s) available for moxifloxacin and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current options and emerging therapies for anterior ocular inflammatory disease.
Topics: Anti-Infective Agents; Antibodies, Monoclonal; Chemokine CCL11; Clinical Trials as Topic; Conjunctivitis, Allergic; Cyclosporine; Dibenzoxepins; Dry Eye Syndromes; Fluoroquinolones; Histamine H1 Antagonists; Humans; Immunotherapy; Levofloxacin; Moxifloxacin; Olopatadine Hydrochloride; Uveitis, Anterior | 2014 |
2 trial(s) available for moxifloxacin and cyclosporine
| Article | Year |
|---|---|
Absence of pharmacokinetic interference of moxifloxacin on cyclosporine and tacrolimus in kidney transplant recipients.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Cyclosporine; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Moxifloxacin; Quinolines; Tacrolimus; Time Factors; Urinary Tract Infections | 2010 |
Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Bone Marrow Transplantation; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Fluoroquinolones; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Moxifloxacin; Quinolines | 2010 |
8 other study(ies) available for moxifloxacin and cyclosporine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Phlyctenular keratoconjunctivitis in a patient with Staphylococcal blepharitis and ocular rosacea.
Topics: Administration, Oral; Administration, Topical; Adult; Aza Compounds; Blepharitis; Cyclosporine; Doxycycline; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratoconjunctivitis; Male; Moxifloxacin; Ophthalmic Solutions; Prednisolone; Quinolines; Rosacea; Staphylococcal Infections | 2008 |
New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens-Johnson Syndrome.
Topics: Acute Disease; Amnion; Anti-Bacterial Agents; Combined Modality Therapy; Cyclosporine; Dexamethasone; Dry Eye Syndromes; Eyelid Diseases; Female; Fluorophotometry; Fluoroquinolones; Glucocorticoids; Guidelines as Topic; Humans; Middle Aged; Moxifloxacin; Prospective Studies; Severity of Illness Index; Stevens-Johnson Syndrome; Tobramycin; Visual Acuity | 2016 |